Background: Administrative claims are an important data source for COPD research but lack a validated measure of patient COPD severity, which is an important determinant of treatment and outcomes. Methods: Patients with !1 diagnosis of COPD and spirometry results from 01/2004-05/2011 were identified from an electronic health records database linked to healthcare claims. Patients were classified into 3 COPD severity groups based on spirometry and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines: GOLD-Unclassified, Mild/Moderate, and Severe/ Very Severe. A multinomial logistic regression model was constructed using claims data from 3 months before and after (observation period) the most recent spirometry (index date) to categorize patient COPD severity. A random selection of 90% of patients in each severity level was selected to build the model, and the remaining 10% were used as a validation sample. Model predictions were evaluated for sensitivity, specificity, accuracy, and concordance. Results: Among 2028 COPD patients who met sample selection criteria, 886, 683, and 459 patients were in the GOLD-Unclassified, Mild/Moderate, and Severe/Very Severe categories, respectively. The final model included age, sex, comorbidities (such as pulmonary fibrosis and Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; ER, emergency room; EHR, electronic health record; FEV 1 , forced expiratory volume for one second; FVC, forced vital capacity; GHP, Geisinger Health Plan; GHS, Geisinger Health System; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICD-9, International Classification of Diseases, Ninth revision. 
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow obstruction to the lungs that is not fully reversible [1] . COPD affects over 24 million American adults [2] and costs approximately $50 billion per year [3] . Given its substantial disease burden, administrative claims are a valuable data source for studying real-world COPD-related economic and health outcomes for large populations, providing rich data on treatment patterns, costs, and healthcare utilization.
For claims analyses, measuring disease severity plays a critical role in accurately characterizing samples, performing statistically valid comparisons, and serving as a study outcome. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines suggest classifying COPD severity based on spirometry e specifically, the forced expiratory volume for one second (FEV 1 ) and the proportion of the forced vital capacity exhaled in the first second (FEV 1 /FVC) [1] . The classification of COPD severity via spirometry is important as it constitutes the basis of treatment recommendations [1] and corresponds to significant differences in health outcomes [4e8] . However, since clinically measured COPD severity is not observable in claims data, claims studies use a wide range of proxies for COPD severity, including comorbidities and evidence of COPD exacerbations [9, 10] . Reliance on proxy measures rather than clinical spirometric data to define COPD severity may be less accurate.
The objective of this study is to use clinically measured COPD severity to develop a claims-based method, which can be used to predict patient severity when pulmonary function data is unavailable. A COPD severity measure developed using clinical data and information readily available in claims as predictors may prove useful when examining COPD in future claims analyses.
Materials and methods

Data source
This study used de-identified data from the Geisinger Health System (GHS), an integrated health system in Pennsylvania comprising over 700 multi-specialty physicians, 3 hospitals, 40 ambulatory clinics, and 3 research centers, which also offers insurance coverage through the Geisinger Health Plan (GHP). GHS database has a cumulative patient base of approximately 3 million lives and includes linked EHR and GHP claims data. This study used linked data from January 2004 to May 2011 for patients with GHP insurance, who account for approximately 50% of all patients in the EHR data. Claims data capture both innetwork and out-of-network (outside GHS) resource use and include medical, hospital, and pharmacy claims for GHP members. EHR pulmonary function test results from spirometry included actual, predicted (based on patient's age and sex), and percent predicted values (actual/ predicted Â 100) for FEV 1 , FVC, and FEV 1 /FVC ratio. For each patient, the most recent spirometry result meeting the following criteria was selected. First, tests with claims data available both 3 months prior to and following were selected. The 3-month post-period was included to capture medication use and treatment following a test, which would likely be associated with COPD severity. Second, in this 6-month window, patients were required to have continuous eligibility in GHP to ensure complete resource utilization information, which excluded patients who potentially died during the observation period, and no recorded asthma diagnoses (ICD-9 code 493) to safeguard against potential misdiagnosis of asthma. Third, spirometry within 1 week of a COPD exacerbation were excluded, as GOLD guidelines categorize severity in reference to a patient's baseline severity. Spirometry during an exacerbation may overstate a patient's underlying severity and can be difficult for a sick patient to perform properly, leading to an inaccurate measurement [1] . COPD exacerbations were identified using a modified version of the algorithm developed by Mapel et al. [10] (e-Appendix 1). If multiple tests were eligible, the most recent spirometry test was selected. Alternatively, choosing the test with the most severe reading among all eligible tests was considered but had no effect on the severity distribution. The 6-month window e 3 months before and after the selected spirometry test e was defined as the observation period.
Study design and sample
COPD severity
Patients were categorized into 4 COPD severity levels (Mild, Moderate, Severe, Very Severe) based on GOLD guidelines (e-Appendix 2) [1] . Patients diagnosed with COPD who could not be categorized into one of the GOLD categories (FEV 1 /FVC ! 0.70) were defined as "GOLD-Unclassified". This separate category was created because, while severity was unidentified by spirometry, it was important to include all COPD-diagnosed patients with a spirometry reading, as these patients would likely be observed in a typical claims database. "GOLD-Unclassified" patients may include those misdiagnosed with other lung conditions, such as pulmonary fibrosis, or COPD patients unable to complete the test because of obesity, which limits the diaphragm's ability to displace intra-abdominal fat [11] . After classifying patients into these categories, the 5 categories were collapsed into 3 levels e GOLD-Unclassified, Mild/Moderate, and Severe/ Very Severe to ensure a reasonable number of patients in each category.
Patient characteristics potentially associated with severity
Patient demographics (e.g., age, gender), medical conditions (e.g., pulmonary vascular disease, osteoporosis), and all-cause and COPD-related healthcare utilization potentially associated with COPD and readily available in claims were selected based on literature review and clinical expert opinion (e-Appendix 3). COPD-related utilization during the 6-month observation period was defined as: an inpatient, emergency room (ER), or outpatient visit with a COPD diagnosis; COPD exacerbation; and COPD medications (e.g., inhaled corticosteroids, short-acting beta-agonists) (e-Appendix 4). COPD-related procedures during the 6-month observation period were also evaluated (eAppendix 5), including: surgery (e.g., lung volume reduction), pulmonary rehabilitation, and oxygen therapy. These variables were descriptively estimated and compared across the 3 severity levels using pairwise comparisons with the GOLD-Unclassified group.
Model construction
A random selection of 90% of patients in each severity level (training sample) was used to develop the model, and the remaining 10% (validation sample) served to validate the model. Univariable multinomial logistic regressions, with the observed COPD severity level as the dependent variable, were performed on the training sample to assess the association between each potential predictor and COPD severity. Each predictor with p < 0.50 for any of the severity categories was included as a potential covariate for the multivariable model.
After the univariable selection of potential predictors, a multivariable multinomial logistic regression model was constructed using the observed COPD severity category as the dependent variable and measures identified in the univariable analysis as potential predictors. Stepwise selection (with threshold p < 0.50) was applied to identify the final set of predictors. For each patient, the probability of being assigned into each COPD severity category was predicted using the multivariable model. Each patient was classified in the category with the highest predicted probability.
Predictive performance
For all patients in the validation sample, the patients' predicted and observed COPD severity categories were compared. Sensitivity (e.g., proportion of patients with Severe/Very Severe COPD classified as having Severe/Very Severe COPD by the model), specificity (e.g., proportion of patients without Severe/Very Severe COPD classified as not having Severe/Very Severe COPD by the model), and accuracy (i.e., proportion of patients classified to their true COPD severity categories) were estimated to assess the model's performance. Concordance statistics (Cohen's Kappa) were estimated to evaluate the agreement between predicted and observed categories. Performance of the model was similarly assessed for the training sample.
All analyses were performed in SAS version 9.2 (SAS Institute Inc., Cary, NC).
Results
Patient characteristics
Among patients with a recorded COPD diagnosis and available EHR data, 2028 patients met all the selection criteria Table 1 Sample selection of chronic obstructive pulmonary disease patients with FEV 1 (actual) spirometry.
Step Description Number of patients and were included in the final sample ( Table 1 ). Out of the 2028 patients, 886 were categorized as GOLD-Unclassified, 683 as Mild/Moderate, and 459 as Severe/Very Severe. A total of 1824 patients were randomly selected for the training sample, leaving 204 patients in the validation sample. Based on a descriptive assessment of patient characteristics, compared to the GOLD-Unclassified category, the Mild/Moderate and Severe/Very Severe categories had a higher proportion of male patients, higher average age, and more COPD-related resource use (Tables 2e4). More evidence of obesity and pulmonary fibrosis was observed for GOLD-Unclassified patients than those with a known level of COPD severity, which is consistent with previous literature [11] .
Prediction model
The final prediction model included demographics, medical conditions, COPD-related resource utilization, and allcause healthcare visits as predictors of three COPD severity categories (Table 5 ). More severe COPD was positively associated with being male and older. Osteoporosis was positively associated with COPD severity; whereas, pulmonary fibrosis, skeletal muscle dysfunction, and obesity were negatively associated with COPD severity. COPD-related ER, inpatient, and outpatient visits and oxygen therapy were positively associated with COPD severity. Other potential predictors of COPD severity, such as respiratory infection, pulmonary vascular disease, and pneumonia, did not demonstrate an association (i.e., did not have a p-value <0.50) so they were not included in the final model.
In the validation sample, the model correctly predicted COPD severity for 62.7% of all patients (kappa Z 0.41), with sensitivity of 77.5%, 52.2%, and 50.0% for GOLDUnclassified, Mild/Moderate, and Severe/Very Severe patients, respectively. Corresponding specificities of the model were 70.4%, 80.0%, and 90.5%, suggesting that the model is highly specific for the Severe/Very Severe category and fairly specific for the Mild/Moderate category. The accuracies were 73.5%, 70.6%, and 81.4% for the GOLDUnclassified, Mild/Moderate, and Severe/Very Severe patients, respectively, demonstrating fairly high accuracy for all 3 categories. Positive predictive values (PPVs) for the three categories were 67.0%, 57.1% and 60.4% and negative predictive values (NPVs) for the three categories were 80.1%, 76.6% and 86.2%, respectively. Predictive performance for the training sample demonstrated similar results (Table 6) .
Discussion
This study used linked claims and EHR data to develop and validate a claims-based algorithm to predict COPD severity. The validated, claims-based severity categories enable researchers using claims data to predict COPD severity in the absence of clinical measures. The algorithm was built using a sample of patients at GHS, a primarily rural, tertiary care center.
The predictive performance of the model suggests that the selected variables provide a reasonable way to differentiate patient severity in future claims analyses. Approximately 63% of patients were correctly categorized by the prediction model. In a null model, with patients randomly classified into one of 3 categories, approximately 33% would be correctly categorized, with sensitivities of 33%, specificities of 67%, and accuracies between 52% and 59%. The proposed model performs better than the null model for patients in all categories and particularly for Severe/Very Severe COPD (specificity of 90.5%). In other words, when applying the prediction model to select Severe/Very Severe patients from a claims dataset, patient categorization is fairly reliable. Moreover, the high sensitivity of the model in predicting patients in the GOLDUnclassified category (77.5%) shows that the model performs well in correctly identifying these difficult-to-classify patients.
Administrative claims databases are an important source of real-world population-based data for epidemiological, health economics, and outcomes research. Claims data offer a way to assess mortality rates for different COPD populations as well as provide healthcare utilization and cost data to study its economic burden. However, COPD severity information is often needed to accurately characterize study populations. For example, if not adequately taken into account, disease severity may confound comparisons of costs or COPD exacerbation rates across two treatment groups.
Claims-based prediction models are often used to predict disease severity in other diseases such as breast cancer [12] , lung cancer [13] , and asthma [14] . These studies found similar levels of performance for their prediction models. The current study provides a prediction model that can be used on typical claims data to estimate patients' COPD severity with reasonable accuracy, thus ensuring access to this crucial variable.
Previous severity algorithms have been constructed for use with clinical or survey data and cannot be directly applied to a claims dataset. In a recent study, Goossens et al. [15] developed an algorithm for COPD severity based on data available from a large respiratory clinical trial of moderate to severe COPD patients. The model was built using observed GOLD severity for all patients, who all had a classifiable COPD severity level. The predictors in this model included demographics (age, sex), body mass index (BMI), smoking history, COPD-related therapies, osteoporosis, and hospital admission in the previous year. Although our study shares several similarities, the Goossens et al. model's performance was worse than our model (unweighted kappa Z 0.151 vs. 0.41). It should be noted that, unlike our model, the Goosens et al. model cannot be applied to a typical claims dataset because clinical indicators such as BMI and smoking history are not available in claims. Further, some patients diagnosed with COPD will not have classifiable COPD severity (GOLD-Unclassified); however, the Goosens et al. model does not address this population. Our current model included the GOLDUnclassified category, thus providing an effective method to identify this patient group in claims. Other survey-based studies have developed similar tools to determine COPD severity using clinical and patient-reported measures not usually available in claims data [16e19]. The prediction model reported here attempts to provide a potential [10,20e26] . For example, Wu et al. [9] developed a severity score based on measures available in claims data using principal components analysis, but their proxy score has not been validated against clinical measures of COPD severity. Mapel et al. classified COPD complexity using comorbid respiratory conditions and medical procedures [10] . In the current study, spirometry results linked to claims data allows for the assessment of the claims-based prediction model using a clinical measure of COPD severity.
Limitations First, the model was constructed using patients with spirometry reported in the EHR; however, patients with b COPD-related outpatient visit, ER visit, and inpatient hospitalization was defined as an outpatient visit, an ER visit, or an inpatient hospital stay, respectively, associated with a primary diagnosis of COPD (first-position ICD-9 codes 491, 492, 496). spirometry may be different than those without, potentially limiting the usefulness of this model for a wider population. Thus, this prediction model is best applied in claims analyses focusing on patients with spirometry. In this study, approximately 14% of COPD patients with EHR data had spirometry, but this is not a limitation of the EHR data, as 88.3% of all patients with spirometry tests recorded in their claims data have corresponding EHR results available. While spirometry is recommended to clinically diagnose COPD, a study by Han et al. [27] also found low spirometry use e less than one-third of newly diagnosed patients had spirometry e and its use for newly diagnosed COPD decreased with age. This study is also subject to the quality of the spirometry tests, which can sometimes be inaccurate [28] .
Second, although asthma is a potential comorbidity associated with COPD, patients with asthma diagnoses were excluded from the study sample to reduce the potential of misdiagnosis. A number of respiratory disease studies suggest excluding patients with overlapping diagnoses (both asthma and COPD) when one of these two diseases are being studied [15, 29] because clinicians might face confusion as to how and if they should differentiate these two diseases [30] . A recent study by Hardin et al. suggests that patients with both COPD and asthma may incur more frequent exacerbations compared to patients with COPD only; however, they found that the presence of asthma was not associated with a significant difference in lung function [31] . This selection criterion eliminated 566 patients (approximately 22%) from the final sample. It is likely that some of the measures selected for the final model would change if these patients had been included, and our model may not be applicable to COPD patients with comorbid asthma. Third, this study used specific ICD-9 codes to identify COPD and its associated conditions, which may differ from those used in future studies. For example, we did not use the ICD-9 code 490 to define COPD. This code is often viewed as lacking specificity for COPD, which increases the potential for misclassification [32, 33] . c Obesity-related conditions were defined as ICD-9 codes for the following conditions: obesity, cholelithiasis (gallstones), osteoarthritis, low back pain, gastroesophageal reflux disease, obstructive sleep apnea, pulmonary embolism, and non-alcoholic fatty liver disease.
d Short-acting b 2 -agonist Z levalbuterol, salbutamol; Long-acting b 2 -agonist Z formoterol, arformoterol, salmeterol; Short-acting anticholinergics Z ipratropium bromide; Long-acting anticholinergics Z tiotropium; Combination short-acting b 2 -agonist plus anticholinergic in one inhaler Z salbutamol/ipratropium; Inhaled glucocorticosteroids Z beclomethasone, budesonide, fluticasone propionate; Combination long-acting b 2 -agonist plus glucocorticosteroids Z formoterol/budesonide, salmeterol/fluticasone propionate; Systemic glucocorticosteroids Z prednisone, methylprednisolone.
While this analysis involved a large database in which all claims were captured, this study involves limitations of all claims analyses, such as potential coding inaccuracies and incomplete claims. COPD treatments may also change over time. To mitigate this issue, we incorporated drugs into our model at the class level. As new classes of COPD treatments become available, our model would need to be updated to incorporate these new drug classes. Further, we used the GOLD classification of COPD severity available at the time of the analysis to define severity. The most recent GOLD severity definition also incorporates exacerbations, the Modified Medical Research Council questionnaire (mMRC) score for breathlessness, and the COPD Assessment Test (CAT) score. While we did include COPD exacerbation as a severity predictor, due to data limitations, we did not use the new COPD severity definition, and developing a claimsbased prediction algorithm aligned with this new definition is a subject for future study. Lastly, further study is needed to assess the generalizability of this model to other patient populations.
Conclusions
In this analysis, a COPD severity prediction model was developed using spirometry and predictors typically available in claims data. The relevant predictors identified included demographics, medical conditions, COPD-related resource utilization, and all-cause healthcare visits. Using claims data provides reliable information regarding health utilization and comorbidities and provides a better prediction model for use in future claims-based analyses. 
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